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Abstract 
 
 
Introduction 
Despite clear guidelines recommendations, most patients with heart failure and reduced ejection-
fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate 
characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that 
did not reach recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers (ARBs) 
and/or beta-blockers.  
Methods 
BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors/ARBs and/or beta-blockers 
in 2516 heart failure patients from 69 centers in 11 European countries who were selected if they were 
suboptimally treated while initiation or uptitration was anticipated and encouraged. Patients who died 
during the uptitration period (n=151) and patients with a LVEF>40% (n=242) were excluded. Median 
follow up was 21 months.  
Results  
We studied 2100 HFrEF patients (76% male; mean age 68 ±12), of which 22% achieved the 
recommended treatment dose for ACE-inhibitor/ARB and 12% of beta-blocker. There were marked 
differences between European countries. Reaching <50% of the recommended ACE-inhibitor/ARB and 
beta-blocker dose was associated with an increased risk of death and/or heart failure hospitalization. 
Patients reaching 50-99% of the recommended ACE-inhibitor/ARB and/or beta-blocker dose had 
comparable risk of death and/or heart failure hospitalization to those reaching ≥100%. Patients not 
reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction had 
the highest mortality rate (for ACE-inhibitor/ARB: HR 1.72; 95% CI 1.43-2.01; for beta-blocker: HR 1.70; 
95% CI 1.36-2.05) 
Conclusion 
Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and 
beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with 
patients reaching ≥100%.  
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Introduction 
 
 
Current evidence based guidelines of the European Society of Cardiology (ESC) recommends treating patients to 
recommended or maximum tolerated dose of beta-blockers and angiotensin-converting-enzyme inhibitors (ACE-
inhibitors), or angiotensin II receptor blockers (ARBs) when ACE-inhibitors are not tolerated (1). There is clear 
evidence from large randomized clinical trials that both ACE-inhibitors and beta-blockers improve clinical outcome 
in patients with mild to moderate heart failure (2–13).  
In all of these studies, patients were uptitrated to pre-specified doses, and therefore these doses are currently 
recommended in all guidelines. This recommendation was supported by randomized controlled studies directly 
comparing low versus high doses, showing (trends towards) superiority of higher doses of ACE-inhibitors and beta-
blocker compared with lower doses (14–16). However, in daily clinical practice, not all patients achieve the 
recommended doses (17–19). This might be caused by low blood pressure and/or heart rate, renal dysfunction and 
electrolyte disturbances, but may also be related to inadequate prescription adherence (19) 
BIOSTAT-CHF is a European project designed to determine profiles of patients with heart failure that do or do not 
respond to recommended therapies, regardless of (anticipated) uptitration (20). This project specifically registered 
reasons for not achieving recommended dose of ACE-inhibitors/ARBs and beta-blockers. Using the data from 
BIOSTAT-CHF, we investigated predictors, reasons and clinical outcome of patients that did not reach 
recommended treatment doses of ACE-inhibitors and beta-blocker.   
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Methods 
 
Patient population 
 
The design of the study and patients have been described elsewhere (20). In brief, in BIOSTAT-CHF participated 69 
centres from 11 countries, the number of patients included in each centre varied between 1 and 157 with a median 
of 24 patients. Patients were aged 18 years with symptoms of new-onset or worsening heart failure, confirmed 
either by a left ventricular ejection fraction (LVEF) of ≤40% or a BNP and/or NT-proBNP plasma levels >400 pg/ml or 
>2,000pg/ml, respectively. Patients needed to be treated with either oral or intravenous furosemide ≥40 mg/day or 
equivalent at the time of inclusion. Patients should not have been previously treated with evidence based therapies 
(ACE-inhibitors /ARBs and beta-blockers) or were receiving ≤50% of the target doses of these drugs at the time of 
inclusion and with an anticipated initiation or uptitration of ACE-inhibitor/ARB and/or beta-blocker therapy by the 
treating physician. The first three months of treatment were predefined to be the optimization phase after which a 
stabilization phase of 6 months was defined. During the optimization phase, initiation or uptitration of ACE-
inhibitor/ARB and/or beta-blocker was done according to the routine clinical practice of the treating physician, who 
were encouraged to follow the ESC guidelines at the time of treatment (table 1) (21). 
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Uptitration 
 
Only patients who reached the end of the 3 months uptitration period were included in this analysis. Patients were 
considered successfully uptitrated when recommended dose for either ACE-inhibitor/ARB or beta-blocker was 
achieved after 3 months of uptitration according to current ESC guidelines (table 1) (21). The achieved dose was 
defined as the highest dose achieved within the uptitration period in percentage of the recommended treatment 
dose for either ACE-inhibitor/ARB or beta-blocker. 
 
Statistical analysis 
 
To determine predictors of reaching the recommended dose, we developed two prediction models to predict the 
percentage of achieved recommended dose of ACE-inhibitors/ARBs and beta-blockers using a stepwise backward 
linear regression model. Both models used 55 clinical and laboratory patient characteristics, all previously reported 
to be associated with mortality and the composite outcome in heart failure patients (see supplementary table S1). 
These methods uses the fitted complete model and computes approximate Wald statistics by computing 
conditional (restricted) maximum likelihood estimates (22). We also performed 1000 bootstrap analyses to get a 
robust selection of important patient characteristics associated with reaching recommended dose and achieved 
dose. We included patient characteristics selected in >40% of the bootstrap analyses (23). A flow-chart of the steps 
taken in this analysis is presented in figure S2. 
In the regression models, for all quantitative patient characteristics, non-linearity was evaluated using restricted 
cubic splines (24). For the patient characteristics showing non-linear relations with the logOdds for reaching 
recommended dose or with the achieved dose, Box-Cox transformations were applied (25,26). We chose the 
Netherlands as reference country because the uptitration results they included the largest number of patients. 
Missing values were imputed 5 times using multi-chain Monte Carlo methods Gibbs sampling (27). The stepwise 
regression bootstrap analyses were done 1000 times on all 5 imputed sets.  
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Survival curves for mortality starting at 3 months of follow-up, and the first occurrence of death or heart failure 
related hospitalization in patients reaching recommended ACE-inhibitor/ARB or beta-blocker dose or not were 
constructed using Kaplan-Meier curves. The predictive value of the achieved dose on survival was evaluated using a 
Cox regression model. We compared mortality, and the combined outcome of mortality and heart failure related 
hospitalization between patients who reached recommended dose or not, adjusted for indication-bias, using 
Kaplan-Meier and Cox regression analysis. Because BIOSTAT-CHF is not a randomized study, the selection of 
patients and the probability of successful uptitration may be biased due to baseline differences among patients. To 
adjust for this treatment indication-bias, all analyses of the effect of uptitration on mortality and heart failure 
hospitalization risk were corrected for the probability of the given treatment (ACE-inhibitor/ARB or beta-blocker). 
We used four methods for correction: Propensity score matching, a double robust estimation analysis, inverse 
probability weighting with the probability to reach recommended dose and a multivariate analysis with treatment 
dose as covariate. Propensity-score matching is used to select patients who were not successfully uptitrated that 
were similar to patients who were successfully uptitrated with respect to the probability of successful uptitration 
(28–30). Double robust estimation combines regression modelling with weighting by the propensity score such that 
the effect estimator is robust to misspecification of one (but not both) of these models (31,32). Inverse probability 
weighting weights each observation by the inverse of the probability of successful uptitration (33). We only report 
results of inverse probability weighting because other methods showed similar results. To calculate the probability 
of successful treatment we used the predictions for successful treatment using a stepwise backward logistic 
regression models. Predictors of reaching recommended ACE-inhibitor/ARB and beta-blocker dose are presented in 
supplementary table S2. 
We then compared mortality between patients divided in three groups according to the reasons for (not) reaching 
recommended doses; a) those who reached the recommended dose, b) those who did not reach the recommended 
dose because of symptoms, side effects or non-cardiac organ dysfunction, and c) those who did not reach the 
recommended dose because of unknown reasons. A Cox regression model was used in comparing these three 
groups. We constructed survival curves for all three groups using Kaplan-Meier curves. 
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Results 
 
From the 2516 patients that were included in BIOSTAT-CHF, 151 patients died within the three months uptitration 
period, 23 patients stopped with the study within three months uptitration period without an event and 242 
patients had a LVEF >40% (characteristics are presented in supplementary table S3). These patients were excluded 
from the present analysis. Baseline characteristics of the remaining 2100 patients are presented in table 2. 
A total of 470 (22%) patients reached recommended dose of ACE-inhibitor/ARB, 16% of patients used an ARB of 
which 20% reached recommended dose compared to 27% of patients using ACE-inhibitors, and 257 (12%) patients 
reached recommended beta-blocker dose. We divided the patients in groups of those that reached 0%, 1-49%, 50-
99%, and ≥100% of recommended treatment dose of ACE-inhibitor/ARB or beta-blocker. This division was based on 
the regression slope of the achieved dose on the mortality hazard (supplementary figure S1) (34). Patient 
characteristics of patients who reached ACE-inhibitor/ARB or beta-blocker dose of 0%, 1-49%, 50-99% or ≥100% of 
recommended dose are presented in table 2 and 3 respectively.  
 
Predictors for lower dose 
 
Independent predictors for achieving lower percentages of recommended ACE-inhibitor/ARB dose were female sex, 
country of inclusion, lower BMI and eGFR, and higher alkaline phosphatase values. Predictors for lower beta-
blocker doses were higher age, country of inclusion, lower heart rate and diastolic blood pressure (DBP) and more 
signs of congestion (supplementary table S4). When the different types of hospitals participating in BIOSTAT-CHF 
(Uuniversity hospitals, large teaching hospitals (non-academic), and small non-teaching hospitals), or sites as 
independent predictors were added to the different models, country differences remained significant. 
Marked differences in dose-uptitration were found across Europe. Lower ACE-inhibitor/ARB and beta-blocker doses 
were achieved in South and Central European countries, while Scandinavian countries achieved higher ACE-
inhibitor/ARB and beta-blocker doses (Figure 1).  
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Association between achieved dose and mortality and/or heart failure related hospitalization 
 
After adjusting for indication bias, patients reaching 0% and 1-49% of recommended ACE-inhibitor/ARB dose had a 
higher risk of mortality (HR 1.76; 95% CI 1.54-1.98, and HR 1.50; 95 %CI 1.33-1.67, respectively) and the combined 
endpoint of death and/or heart failure hospitalization (HR 1.77; 95% CI 1.61-1.94, and 1.23; 95 %CI 1.09-1.36, 
respectively), while patients who reached ACE-inhibitor/ARB doses between 50-99% of recommended dose had a 
similar risk of death and the combined endpoint of death and/or heart failure related hospitalization compared to 
those reaching ≥100% of recommended treatment dose (HR 0.82; 95% CI 0.62-1.02 and HR 0.86; 95% CI 0.71-1.00 
respectively). All hazard ratios are presented in table 4, with the addition of the number of patients in each group 
and event rate. 
Patients reaching 0% and 1-49% of recommended dose of beta-blocker had a higher risk of mortality (HR 2.41; 95% 
CI 2.13-2.68, and HR 1.91; 95 %CI 1.74-2.08, respectively) and the combined endpoint of death and/or heart failure 
hospitalization (HR 1.51; 95 %CI 1.29-1.72, and HR 1.27; 95 %CI 1.15-1.39, respectively), while patients who 
reached beta blocker doses between 50-99% of recommended dose had a similar risk of the combined endpoint of 
death and/or heart failure related hospitalization (HR 1.04; 95% CI 0.89-1.20), but an increased risk of death (HR 
1.29; 95% CI 1.07-1.51) compared to those reaching ≥100% of recommended treatment dose. Kaplan Meier 
survival curves for achieving 0%, 1-49%, 50-99% and ≥100% of recommended ACE-inhibitor/ARB and beta-blocker 
dose are presented in figure 2. In supplementary figure 3 Kaplan Meier curves are presented for patients achieving 
≥100% recommended dose for both ACE-inhibitor/ARB and beta-blocker, ≥50% recommended ACE-inhibitor and 
beta-blocker dose, ≥50% of at least ACE-inhibitor/ARB or beta-blocker recommended dose, and for patients 
achieving <50% of recommended ACE-inhibitor/ARB and beta-blocker dose. 
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Reasons for not achieving recommended doses and their effect on mortality 
 
BIOSTAT specifically recorded reasons for not achieving recommended doses (supplementary table S5). We divided 
the patients in three groups: a) those who reached the recommended dose; b) those who did not reach the 
recommended dose because of symptoms, side effects or non-cardiac organ dysfunction and c) those who did not 
reach the recommended dose because of other/unknown/not specified reasons.  
Patients not reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction 
(group b) had the highest mortality rate as presented in figure 4. For ACE-inhibitor/ARB, the hazard for not reaching 
recommended dose because of symptoms, side effects and non-cardiac organ dysfunction was 1.72; 95% CI 1.43-
2.01 and the HR for ‘other reasons’ was 1.46; 95% CI 1.19-1.73 (p-value for difference between these groups = 
0.1457). Not reaching the recommended dose of beta blockers because of symptoms, side effects and non-cardiac 
organ dysfunction was associated with an increased mortality risk (HR 1.70; 95% CI 1.36-2.05) while the mortality 
risk was not increased in patients who did not reach the recommended dose for ’other reasons’ (HR 1.18; 95% CI 
0.86-1.50; p-value for difference between these groups = 0.0001). Patient characteristics of all three groups for 
ACE-inhibitors/ARBs and beta-blockers are presented in supplementary table S6. Patients not reaching 
recommended ACE-inhibitor/ARB and beta-blocker dose because of symptoms, side effects or non-cardiac organ 
dysfunction had significantly higher LVEF (p= 0.04, and p= 0.04, respectively) and NT-proBNP (p= 0.0005, and p= 
0.02, respectively) compared to patients not reaching recommended dose because of other/unknown reasons. 
Additionally, patients not reaching beta-blocker dose were somewhat older (p=0.08), had were longer diagnosed 
with heart failure (p=0.07), had more AF (p=0.06) and lower DBP (p=0.08).  
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Discussion 
 
The aim of this study was to establish characteristics and clinical outcomes of non-successful uptitration of 
recommended therapies in patients with heart failure. After an uptitration phase, only in 22% of patients the 
recommended doses of ACE-inhibitors/ARBs, and in 12% of patients the recommended doses of the beta-blockers 
were achieved. These numbers are lower compared with clinical trials, but similar to heart failure registries (4–
9,35–38). Higher success rates were mainly achieved in studies in mild to moderate CHF patients in clinical trial 
settings. Trial setting results might overestimate uptitration success in daily clinical patient population, since 
generally more motivated patients will accept trial participation and close monitoring of clinical trials will lead to 
better application of the guidelines. Data from the European Society of Cardiology Heart Failure Pilot Survey 
showed that ramipril and enalapril were the most prescribed ACE-inhibitors; the target dose of  these drugs was 
achieved in 38% and 46% of the cases, respectively (39). The target dose of carvedilol, bisoprolol, and metoprolol 
was reached in 37%, 21%, and 21% of patients. In the CIBIS-ELD study, elderly patients from 41 cardiology centers, 
only 25% of patients reached and maintained guideline-recommended target doses of bisoprolol/carvedilol after 12 
weeks treatment (40). In a UK primary care cohort study of 12493 patients, only 17.8% reached the recommended 
beta-blocker dose (18). Using a structured treatment of CHF according to guidelines in a Swedish trial with heart 
failure patients in the primary care setting, a marked increase in the recommended doses of ACE-inhibitors and 
beta-blockers was achieved (41). BIOSTAT-CHF was not a clinical trial, but patients were still younger and more 
often male compared with the general heart failure population. This is related to the inclusion criteria of the study 
and the setting of cardiology clinics. It should be noted that patients could only enter the study if they were 
receiving ≤50% of the target doses of these drugs at the time of inclusion and with an anticipated initiation or 
uptitration of ACE-inhibitor/ARB and/or beta-blocker therapy by the treating physician.  
Patients more likely to achieve lower ACE-inhibitor/ARB dose doses were female, had lower BMI and eGFR, higher 
alkaline phosphatase values and were more often treated in South and Central European countries. Patients more 
likely to achieve lower beta-blocker doses were older had lower heart rates and DBP, more signs of congestion and 
were also more often treated in South and Central European countries. The relationship between BMI, eGFR and 
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prognosis and uptitration dose is previously reported (42–46). It is not clear why female patient achieved lower 
ACE-inhibitor/ARB doses, this might be because they have lower body weight. Similarly, it is not clear why elevated 
alkaline phosphatase is associated with lower achieved doses Some of the ACE-inhibitors and ARBs (enalapril, 
ramipril, fosinopril, trandolapril, quinapril, benazepril, moexipril, and losartan) are prodrugs, and require 
transformation by the liver into active metabolites. With liver dysfunction, decreases in prodrug transformation 
and inactivation of active drug may occur, although this is highly speculative (47,48). The ESC guidelines advices to 
reduce beta-blocker dose when patients have low heart rate (<50 b.p.m.) or asymptomatic low blood pressure and 
increasing congestion (1), this is in line with our findings of predictors for lower beta-blocker doses. Differences 
found between European countries were remarkable. The most pronounced difference is between the 
Scandinavian countries and the Southern European countries. These differences might be a reflection of differences 
in national health systems and different local practice or differences in patient characteristics. 
We found that reaching less than 50% of the recommended doses of both ACE-inhibitor/ARBs and beta-blockers 
resulted in significant poorer survival. This is in line with previous published trials (2,6,8,16,49–51). Because 
BIOSTAT-CHF patients were systematically uptitrated to recommended treatment or maximum tolerated doses 
according to the guidelines, it enabled us to compare the effects of achieved dose on mortality, and mortality 
and/or heart failure related hospitalization. 
Patients who achieved doses 50-99% of the recommended dose for beta-blockers had significantly worse survival 
than patient reaching recommended dose, but a similar risk of the combined endpoint of mortality and/or heart 
failure related hospitalization. For ACE-inhibitors/ARB, patients reaching 50-99% of recommended dose a similar 
rates of mortality and the combined endpoint of mortality and/or heart failure related hospitalization. Although 
highly speculative, this would suggest that the optimal treatment dose for ACE-inhibitor/ARB could be less than the 
recommended dose, and may vary between 50 and 100% of the current recommended dose. There is little known 
about the comparison of 0%, 1-49%, 50-99% and ≥100% of recommended ACE-inhibitors/ARBs doses. The 
Results of CONSENSUS (10), SOLVD (11,12) and V-HeFT II (13) trials have clearly shown benefit of ACE-inhibitors at 
high doses. The NETWORK trial (50) compared 25%, 50% and 100% of recommended enalapril dose, although there 
was a trend in mortality reduction they did not find any significant difference in mortality and heart failure related 
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hospitalizations. The ATLAS trial (14) suggests that higher doses does reduce heart failure related hospitalizations 
(p=0.002). They compared 2.5-5 mg daily lisinopril (7%-14% of the recommended lisinopril dose) to 32.5 to 35 mg 
daily (93%-100% of the recommended dose). The HEAAL trial (16) compared 33% to 100% of the recommended 
losartan dose. They found a significant difference in all-cause mortality and/or heart failure related hospitalization 
(p=0.027). The CIPS trial (52) evaluated 33% versus 66% of the recommended captopril dose and did only find a 
trend toward reduction of heart failure related hospitalization, but this trial only included 298 patients and did not 
have enough power. Nanas et al. compared recommended enalapril dose to high (300%) dose, but did not found 
significant differences in survival (53). 
BIOSTAT-CHF was specifically designed to record reasons for not achieving the recommended doses. Only in 26% 
and 22% of the patients for ACE-inhibitors/ARBs and beta-blockers, this was caused by intolerance to the drug, 
either because of organ dysfunction (e.g. renal dysfunction) or it was related to symptoms and/or side effects (e.g. 
dizziness). Patients who could not be uptitrated because of symptoms, side effects and non-cardiac organ 
dysfunction had the highest mortality rate, both with regards to the ACE-inhibitors/ARB and beta-blockers. This 
supports previous findings of a post-hoc analysis of the SENIORS trial, patients intolerant to any dose of nebivolol 
had a markedly higher risk of death or CV hospitalization compared with placebo (54). In the majority of patients, 
no specific reason was provided. This high percentage of ’other reasons’ could have many causes. Perhaps the 3-
month period for uptitration was too short, and physicians were still uptitrating treatment dose when the 3 months 
of uptitration period passed. Another reason might be lack of patient compliance. A third reason might be related 
to non-compliance of physicians to the recommendation provided in the guidelines. The observation that patients 
in which recommended doses of ACE-inhibitor/ARB and beta-blocker was not achieved because of drug intolerance 
had a higher mortality than patients for which no reason was specified. 
Regardless of the design of BIOSTAT-CHF and efforts to record all reasons for dose change, we lack further 
specification of reasons for not achieving recommended dose other than ’unknown’. 
In this manuscript we corrected for indication bias using three different methods (propensity score matching, 
double robust estimation, and inverse probability weighting). All of these methods gave similar results. This 
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strengthens the belief we adequately corrected for indication bias, but whether we corrected sufficiently for all 
bias is unfortunately not testable. 
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Conclusion 
 
Despite the encouragement to follow the ESC Heart Failure Guidelines, only 22% patients reached recommended 
dose of ACE-inhibitor/ARB and 12% of patients achieved recommended dose for beta-blocker. Independent 
predictors of reaching lower ACE-inhibitor/ARB doses were country of inclusion, female gender, lower BMI and 
eGFR, and higher alkaline phosphatase, while predictors for lower doses of beta-blockers were higher age, country 
of inclusion and lower DBP, heart rate and more signs of congestion. Reaching less than 50% of the recommended 
dose of ACE-inhibitor/ARB and beta-blocker doses was associated with worse survival. In most patients, no specific 
reason for not reaching the recommended dose could be provided. Patients who did not reach the recommended 
ACE-inhibitor/ARB or beta-blocker dose because of intolerance had worse survival compared to patients when 
there was another reason for not reaching recommended dose. 
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Table 1: Recommended doses of ACE-inhibitors, ARBs and beta-blockers in ESC guidelines  
for patients with LVEF <40%. q.d.=once a day; b.i.d.=twice a day; t.i.d.=3 times a day 
 
Drug Class Target dose Total daily dose 
 
Captopril ACE-inhibitor 50 mg t.i.d. 150 mg 
 Enalapril ACE-inhibitor 10 mg b.i.d. 20 mg 
 Lisinopril ACE-inhibitor 35 mg q.d. 35 mg 
 
Ramipril ACE-inhibitor 5 mg b.i.d. or 10 mg q.d. 10 mg 
 Trandolapril ACE-inhibitor 4 mg q.d. 4 mg 
 Perindopril ACE-inhibitor 8 mg q.d. 8 mg 
 Candesartan ARB 32 mg q.d. 32 mg 
 Valsartan ARB 160 mg b.i.d. 320 mg 
 Losartan ARB 150 mg q.d. 150 mg 
 Bisoprolol Beta-blocker 10 mg q.d. 10 mg 
 Carvedilol Beta-blocker 25-50 mg b.i.d. 50-100 mg* 
 
Metoprolol CR/XL Beta-blocker 200 mg q.d. 200 mg 
 Nebivolol Beta-blocker 10 mg 10 mg 
 *25 mg b.i.d. for patients weighing <75 kg and  
50 mg b.i.d. for patients weighing >75 k 
 
 
  
Table 2: Patient characteristics, with n (percentage), mean (sd) or median (interquartile range), at baseline for all patients and for patients 
who reached 0%, 1-49%, 50-99 and ≥100% of recommended ACE-inhibitor/ARB dose after uptitration period. 
 
   All patients 0% 1-49% 50-99%  ≥100%  p-value 
n 2100 305 686 639 470 
 Sex (Male) 1589 (76%) 234 (77%) 520 (76%) 474 (74%) 361 (77%) 0.73 
Race (Caucasian) 2078 (99%) 304 (100%) 677 (99%) 634 (99%) 463 (99%) 0.53 
Age (years) 68 (12) 70 (12) 68 (12) 67 (12) 67 (12) 0.001 
Ischemic aetiology 1154 (55%) 181 (59%) 373 (54%) 356 (56%) 244 (52%) 0.22 
Previous Hospitalization in past year 
before baseline 
669 (32%) 120 (39%) 239 (35%) 185 (29%) 125 (27%) 0.0003 
HF duration (years) 8 (3.6-13.3) 5.7 (2.3-10.1) 8.7 (5.3-13.7) 8.6 (4.6-13.5) 8.5 (4-14.1) 0.14 
Atrial Fibrillation 901 (43%) 147 (48%) 316 (46%) 248 (39%) 190 (40%) 0.01 
Diabetes mellitus 676 (32%) 102 (33%) 201 (29%) 198 (31%) 175 (37%) 0.03 
Hypertension 1277 (61%) 177 (58%) 366 (53%) 399 (62%) 335 (71%) <0.00001 
Body mass index (kg/m^2) 28 (5.52) 27.5 (5.25) 27.1 (5.08) 28.1 (5.34) 29.4 (6.21) <0.00001 
Heart rate (beats/min) 79 (19) 78 (17) 81 (20) 80 (19) 80 (21) 0.52 
Systolic blood pressure (mmHg) 124 (21) 119 (22) 119 (20) 126 (20) 133 (22) <0.00001 
Diastolic blood pressure (mmHg) 76 (13) 72 (12) 73 (12) 77 (13) 80 (14) <0.00001 
LVEF (%) 30 (25-35) 30 (25-35) 27 (21-33) 30 (25-35) 30 (25-35) 0.001 
NT-proBNP (ng/L) 4138 (2249-8220) 5947 (2955-11788) 4565.5 (2509-8859) 4131 (2081-7529) 3274 (2015-5847) 0.00001 
eGFR (ml/min/1.73m^2) 66.7 (23.66) 56.8 (25.11) 65 (23.79) 69.9 (22.2) 71 (22.35) <0.00001 
% ACE-inhibitor/ARB target dose 50 (25-75) 0 (0-0) 25 (14.3-25) 50 (50-50) 100 (100-100) <0.00001 
% beta-blocker target dose 25 (12.5-50) 25 (12.5-50) 25 (12.5-50) 25 (12.5-50) 50 (25-75) <0.00001 
eGFR: estimated glomerular filtration rate; HF: heart failure; LVEF: Left ventricular ejection fraction; n: Number of patients; NT-proBNP: N-terminal pro B-type natriuretic peptide 
  
 Table 3: Patient characteristics, with n (percentage), mean (sd) or median (interquartile range), at baseline for all patients and for  patients 
who reached 0%, 1-49%, 50-99 and ≥100% of recommended beta-blocker dose after uptitration period 
 
  All patients 0% 1-49%   50-99% ≥100% p-value 
n 2100 200 1062 581 257 
 Sex (Male) 1589 (76%) 136 (68%) 823 (78%) 444 (76%) 186 (72%) 0.02 
Race (Caucasian) 2078 (99%) 199 (100%) 1050 (99%) 575 (99%) 254 (99%) 0.90 
Age (years) 68 (12) 70 (12) 68 (12) 67 (12) 67 (13) 0.02 
Ischemic aetiology 1154 (55%) 103 (52%) 604 (57%) 318 (55%) 129 (50%) 0.18 
Previous Hospitalization in past year 
before baseline 
669 (32%) 70 (35%) 326 (31%) 181 (31%) 92 (36%) 0.32 
HF duration (years) 8 (3.6-13.3) 8.8 (4.4-13.9) 6.7 (3.3-11.7) 8.3 (3.7-13.4) 9 (4.7-18) 0.49 
Atrial Fibrillation 901 (43%) 85 (43%) 432 (41%) 255 (44%) 129 (50%) 0.05 
Diabetes mellitus 676 (32%) 68 (34%) 356 (34%) 169 (29%) 83 (32%) 0.29 
Hypertension 1277 (61%) 105 (53%) 654 (62%) 359 (62%) 159 (62%) 0.09 
Body mass index (kg/m^2) 28 (5.52) 27.9 (5.91) 28 (5.32) 28.1 (5.7) 27.9 (5.67) 0.85 
Heart rate (beats/min) 80 (19) 76 (18) 78 (18) 81 (20) 86 (23) <0.00001 
Systolic blood pressure (mmHg) 124 (21) 121 (21) 123 (21) 127 (22) 126 (20) 0.001 
Diastolic blood pressure (mmHg) 76 (13) 71 (12) 75 (12) 78 (14) 78 (13) <0.00001 
LVEF (%) 30 (25-35) 30 (25-35) 30 (24-35) 30 (25-35) 30 (25-35) 0.97 
NT-proBNP (ng/L) 4138 (2249-8220) 3282 (1542-8522) 4534 (2503-8806) 3953 (2337-7494) 3676 (2040-7541) 0.04 
eGFR (ml/min/1.73m^2) 66.7 (23.66) 64.5 (22.82) 66.4 (23.68) 66.6 (23.17) 69.3 (25.13) 0.05 
% ACE-inhibitor/ARB target dose 50 (25-75) 25 (15.8-50) 38 (13-50) 50 (25-100) 50 (25-100) <0.00001 
% beta-blocker target dose 25 (12.5-50) 0 (0-0) 25 (12.5-25) 50 (50-50) 100 (100-100) <0.00001 
eGFR: estimated glomerular filtration rate; HF: heart failure; LVEF: Left ventricular ejection fraction; n: Number of patients; NT-proBNP: N-terminal pro B-type natriuretic peptide 
 
  
 Table 4: Hazard ratios and number of events of achieving 4 different levels of recommended treatment dose (0%, 1-49% 50-99% and ≥100%) 
for mortality, heart failure related hospitalization and the first occurrence of death or heart failure related hospitalization. 
 
 
ACE-inhibitor/ARB Beta-blocker 
 
0% 1-49% 50-99%  ≥100%  0% 1-49% 50-99%  ≥100%  
n 305 686 639 470 200 1062 581 257 
Mortality rate, % (n) 29% (89) 25% (172) 14% (92) 15% (70) 27% (53) 22% (233) 16% (93) 17% (44) 
Mortality and/or HF-
hospitalization rate, % (n) 
50% (152) 39% (267) 29% (185) 29% (137) 41% (82) 36% (286) 31% (182) 35% (91) 
HR Mortality  1.76 (1.54-1.98) 1.50 (1.33-1.67) 0.82 (0.61-1.02) - 2.41 (2.13-2.68) 1.91 (1.74-2.08) 1.29 (1.07-1.51) - 
HR Mortality and/or HF-
hospitalization  
1.77 (1.61-1.94) 1.23 (1.09-1.36) 0.86 (0.71-1.00) - 1.51 (1.29-1.72) 1.27 (1.15-1.39) 1.04 (0.89-1.20) - 
CI: confidence interval; HF: heart failure; HR: hazard ratio; n: Number of patients 
 
  
 Figure 1. Average percentage achieved of the recommended dose of ACE-inhibitor/ARB (left), and beta-blocker (right) per country 
 
 
  
 Figure 2: Adjusted mortality rate for patients receiving 0%, 1-49%, 50-00% or ≥100% of the recommended ACE-inhibitor/ARBs or beta-blocker 
dose, together with the risk set sizes at each time point. 
 
  
 Figure 3: Adjusted mortality rate for patients achieving or ≥100% for both ACE-inhibitor/ARB and beta-blocker recommended dose, ≥50% 
recommended ACE-inhibitor and beta-blocker dose, ≥50% of at least ACE-inhibitor/ARB or beta-blocker recommended dose, and for patients 
achieving <50% of recommended ACE-inhibitor/ARB and beta-blocker dose. 
 
 
 
  
 Figure 4: Adjusted mortality rate for patients a) receiving recommended dose; b) reached less than recommended dose due to symptoms, 
side effects or non-cardiac organ failure and c) reached less than recommended dose for other reasons, together with the risk set sizes at 
each time point. 
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Supplementary data 
Table S1: Baseline patient characteristics. All were used in regression analyses. Given in either numbers 
(percentages), mean (sd), median (interquartile range) 
 
Description of baseline patient characteristics   
n 2100 
Sex (Male) 1589 (76%) 
Age (years) 68 (12) 
Country 
 Netherlands 276 (13%) 
Germany 84 (4%) 
France 195 (9%) 
Greece 278 (13%) 
Italy 289 (14%) 
Norway 93 (4%) 
Poland 244 (12%) 
Serbia 366 (17%) 
Slovenia 22 (1%) 
Sweden 96 (5%) 
United Kingdom 157 (8%) 
Smoking 
 no 772 (37%) 
past 1026 (49%) 
current 302 (14%) 
Alcohol usage 595 (28%) 
Body Mass Index (kg/m2) 28 (5.52) 
Heart Rate (bpm) 80 (19) 
Systolic Blood Pressure (mmHg) 124 (21) 
Diastolic Blood Pressure (mmHg) 76 (13) 
Left ventricular ejection fraction (%) 29 (7.5) 
NYHA Class 
 I 54 (3%) 
II 760 (37%) 
III 1004 (49%) 
IV 232 (11%) 
Ischemic heart disease 1154 (55%) 
Hospitalization in past year before baseline  669 (32%) 
HF duration (years) 8 (3.6-13.3) 
Atrial Fibrillation 901 (43%) 
Diabetes 676 (32%) 
eGFR (ml/min/1.73m^2) 66.7 (23.66) 
Myocardial Infarction 822 (39%) 
Coronary Artery Bypass Graft 344 (16%) 
Coronary artery disease 957 (46%) 
Percutaneous Coronary Intervention 473 (23%) 
Stroke 187 (9%) 
Peripheral Arterial Disease 214 (10%) 
Chronic Obstructive Pulmonary Disease 344 (16%) 
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Pulmonary congestion 
 Single base 260 (13%) 
Bi-basilar 756 (37%) 
Peripheral oedema  988 (47%) 
Elevated Jugular venous pressure 442 (30%) 
Hepatomegaly 291 (14%) 
3rd  Heart Tone 220 (11%) 
Rales > 1/3 up lung fields 183 (18%) 
Orthopnea present 678 (32%) 
Baseline Medication 
      Haematocrit (%) 40.5 (5.26) 
     Blood urea nitrogen (mmol/L) 10.8 (7.3-17.17) 
     N-terminal pro b-type natriuretic peptide e (pg/ml) 4138 (2249-8220) 
     Haemoglobin (g/L) 13.4 (1.85) 
     Sodium (mmol/L) 139.2 (3.83) 
     Potassium (mmol/L) 4.3 (0.55) 
     B-type natriuretic peptide (BNP) (pg/ml) 637 (291-1197) 
     Bilirubin (µmol/L) 14 (9.92-20.61) 
     Total-cholesterol (mmol/L) 4.3 (1.36) 
     HDL-cholesterol (mmol/L) 1.1 (0.39) 
     HEPC 6.5 (2.3-17) 
     Soluble Transferrin Receptor (mg/L) 1.5 (1.14-2.02) 
     Free Thyroxine (FT4) pmol/L) 15.8 (13.16-18.9) 
     HBA1C 6.3 (5.74-7.12) 
     ASAT (U/L) 25 (17-38) 
     ALAT (U/L) 25 (19-35) 
     TSH (mU/L) 1.8 (1.19-2.9) 
     Proteinuria (mg/dL) 5 (0-19.25) 
     Gamma-GT (U/L) 54 (28-103) 
     Alkaline Phophatase (ug/L) 84 (64.98-117) 
     TnI (pg/mL) 12.2 (6.56-25.87) 
     ET-1 (pg/mL) 5.2 (3.93-6.93) 
     bio-ADM (pg/mL) 31.8 (21.95-49.67) 
     Troponin (ug/L) 0.04 (0.01-0.1) 
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Table S2: Results of logistic regression for reaching recommended ACE-inhibitor/ARB or beta-blocker 
dose. These results are used for predicting the probabilities of receiving recommended treatment in the 
inverse probability weighting. Negative estimates represent a negative relation, so Norwegian patients 
have a higher probability of being uptitrated, while patients from Italy low compared to patient from the 
Netherlands.  
 
 
ACE-inhibitor/ARB Beta-Blocker 
  Estimate Std. Error p-value Estimate Std. Error p-value 
Intercept -6.38 0.48 <0.0001 -2.48 0.339 <0.0001 
Country   
 
  
   Netherlands - - - - - - 
Germany -0.32 0.345 0.36 -1.08 0.453 0.02 
France 0.23 0.233 0.32 -0.13 0.241 0.58 
Greece -0.81 0.245 0.001 -2.02 0.371 <0.0001 
Italy -0.22 0.224 0.32 -0.51 0.236 0.03 
Norway 1.19 0.269 <0.0001 0.27 0.279 0.33 
Poland -0.41 0.234 0.08 -1.06 0.284 <0.0001 
Serbia 0.26 0.195 0.18 -1.58 0.293 <0.0001 
Slovenia 0.33 0.497 0.5076 0.91 0.472 0.05 
Sweden 1.25 0.265 <0.0001 0.9 0.265 <0.0001 
United Kingdom 0.19 0.254 0.45 -1.86 0.443 <0.0001 
Body mass index (kg/m^2) 
0.06 0.01 <0.0001 
   Systolic blood pressure (per 10 mmHg) 0.22 0.026 <0.0001 
   eGFR (per 10 ml/min/1.73m^2) 0.1 0.024 <0.0001 
   Heart rate (per 10 bpm)       0.13 0.033 <0.0001 
 
 
 
  
Table S3: Patient characteristics of the included patients and excluded patients, those with LVEF>40%, died within 3 months of up-titration 
period, and who stopped with the study within three months up-titration period without an event 
 
 
   
  Excluded patients 
 
included patients LVEF>40% died right censored p-value 
n 2100 242 151 23   
Sex (Male) 1589 (75.7%) 135 (55.8%) 105 (69.5%) 17 (73.9%) <0.0001 
Race (Caucasian) 2078 (99%) 240 (99.2%) 150 (99.3%) 21 (91.3%) <0.0001 
Age (years) 67.7 (11.95) 76 (9.12) 74.4 (10.77) 67.8 (10.29) <0.0001 
Ischemic aetiology 1154 (55%) 100 (41.3%) 90 (59.6%) 14 (60.9%) 0.0003 
Previous Hospitalization in past year before baseline 669 (31.9%) 62 (25.6%) 53 (35.1%) 10 (43.5%) 0.09 
HF duration (years) 8 (3.55-13.27) 8.9 (3.97-15.16) 11.1 (3.08-14.7) 0 0.83 
Artrial Fibrilation 901 (42.9%) 151 (62.4%) 82 (54.3%) 9 (39.1%) <0.0001 
DM 676 (32.2%) 87 (36%) 49 (32.5%) 7 (30.4%) 0.69 
Hypertension 1277 (60.8%) 182 (75.2%) 96 (63.6%) 14 (60.9%) 0.0002 
Body mass index (kg/m^2) 28 (5.52) 28 (5.71) 26.4 (4.83) 26.7 (3.37) 0.004 
Heart rate (beats/min) 79.8 (19.43) 80 (20.11) 82.5 (19.62) 77.7 (15.35) 0.3 
Systolic blood pressure (mmHg) 124.2 (21.24) 132.7 (25.98) 119.3 (21.25) 122.3 (19.88) 0.83 
Diastolic blood pressure (mmHg) 75.5 (13.05) 72.5 (16.02) 70.6 (11.65) 74.2 (14.92) <0.0001 
LVEF (%) 30 (25-35) 50 (45-57.5) 30 (21.5-38) 30 (27.5-35) <0.0001 
NT-proBNP (ng/L) 4138 (2249-8220) 3810 (2440-7391) 9326 (4139.5-16415.75) 5188.5 (2781.75-13837.5) <0.0001 
eGFR (ml/min/1.73m^2) 66.7 (23.66) 60.6 (22.95) 52.2 (23.78) 65.5 (19.89) <0.0001 
% ACE target dose 50 (25-75) 25 (0-50) 13 (0-44) 25 (13.6-50) <0.0001 
% BB target dose 25 (12.5-50) 38 (12.5-50) 12 (0-37.5) 25 (12.5-50) <0.0001 
 Table S4: Results of linear regression for achieving lower percentages of recommended ACE-inhibitor/ARB or beta-blocker doses. Negative 
values represent higher percentage of recommended dose, while positive values are associated with achieving lower recommended doses. 
 
ACE-inhibitor/ARB Beta-blocker 
  Estimate Std. Error p-value Estimate Std. Error p-value 
Intercept 92.46 4.692 <0.0001 71.46 6.199 <0.0001 
Age (per 10 years) 
  
  1.7 0.532 0.001 
Gender (female) 4.39 1.708 0.01   
  Country 
  
    
  Netherlands - - - - - - 
Germany 2.12 4.075 0.60 0.29 3.582 0.9347 
France -0.38 3.05 0.90 2.17 2.652 0.4127 
Greece 10.58 2.782 <0.0001 22.41 2.43 <0.0001 
Italy 15.88 2.754 <0.0001 6.85 2.416 0.005 
Norway -13.58 3.908 <0.0001 -2.96 3.383 0.38 
Poland 11.26 2.879 <0.0001 12.39 2.521 <0.0001 
Serbia -4.66 2.609 0.07 16.19 2.328 <0.0001 
Slovenia -2.54 7.215 0.73 -11.7 6.265 0.06 
Sweden -18.69 3.858 <0.0001 -13.18 3.381 <0.0001 
United Kingdom 3.17 3.269 0.33 17.41 2.836 <0.0001 
Diastolic blood pressure (per 10 mmHg) 
  
  -2.63 0.498 <0.0001 
Body mass index (kg/m^2) -0.95 0.13 <0.0001   
  
Heart rate (per 10 bmp) 
  
  -1.62 0.344 <0.0001 
Alkaline Phosphatase (per 10 µg/L) 0.26 0.119 0.07   
  eGFR (per 10 ml/min/1.73m^2)  -2.79 0.309 <0.0001   
  Pulmonary congestion 
  
    
  No   
 
  - - - 
Single base   
 
  4.21 1.953 0.03 
Bi-basilar       5.31 1.383 <0.0001 
  
  
Table S5: CRF page of ACE-inhibitor/ARB and Beta-blocker to fill in uptitration result 
 
 
ACE-inhibitor/ARB 
      
Drug name* 
Total daily dose 
(mg)  
Start date 
(dd/mm/yyyy)  
End date 
(dd/mm/yyyy)  
Ongoing at 9 
month visit  Reason # 
 
Specify reason 
            
 
       
       
       
Beta-blocker 
      
Drug name* 
Total daily dose 
(mg)  
Start date 
(dd/mm/yyyy)  
End date 
(dd/mm/yyyy)  
Ongoing at 9 
month visit  Reason # 
 
Specify reason 
       
       
       
       
*also include drugs stopped within 3 months before inclusion 
    
       
reasons # 
      
1=Non optimal dose acc. to 
ESC guidelines;  
      
2=Symptoms;  
      
3=Side effects ; 
      
4=Non-cardiac organ dysfunction; 
     
99=Other, specify  
      
 Table S6: Patient characteristics, with n (percentage), mean (sd) or median (interquartile range), at baseline for all patients and for  patients a) 
receiving recommended dose; b) reached less than recommended dose due to symptoms, side effects or non-cardiac organ failure and c) 
reached less than recommended dose for other reasons for ACE-inhibitor/ARBs and beta-blockers 
  
ACE-inhibitor/ARB Beta-blocker 
  
All patients recommended dose 
symptoms, side 
effects or non-
cardiac organ 
dysfunction 
other/unknown/not 
specified reasons p-value recommended dose 
symptoms, side 
effects or non-
cardiac organ 
dysfunction 
other/unknown/not 
specified reasons p-value 
n 2100 470 553 1077   257 453 1390 
 Sex (Male) 1589 (76%) 361 (77%) 408 (74%) 820 (76%) 0.46 186 (72%) 333 (74%) 1070 (77%) 0.14 
Race (Caucasian) 2078 (99%) 463 (99%) 550 (100%) 1065 (99%) 0.27 254 (99%) 451 (100%) 1373 (99%) 0.69 
Age (years) 68 (12) 67 (12) 68 (12) 68 (12) 0.08 67.2 (13) 68.6 (12) 67.5 (12) 0.17 
Ischemic aetiology 1154 (55%) 244 (52%) 309 (56%) 601 (56%) 0.32 129 (50%) 254 (56%) 771 (56%) 0.26 
Previous Hospitalization in past year 
before baseline 669 (32%) 125 (27%) 180 (33%) 364 (34%) 0.02 92 (36%) 147 (33%) 430 (31%) 0.29 
HF duration (years) 8 (3.6-13.3) 9.6 (2.6-16.3) 8 (2.3-14.5) 7.6 (2.3-16.1) 0.01 8.7 (2.6-16.3) 9 (2.4-16.7) 7.7 (2.3-15.2) 0.13 
Artrial Fibrilation 901 (43%) 190 (40%) 245 (44%) 466 (43%) 0.43 129 (50%) 207 (46%) 565 (41%) 0.01 
Diabetes mellitus 676 (32%) 175 (37%) 169 (31%) 332 (31%) 0.03 83 (32%) 148 (33%) 445 (32%) 0.97 
Hypertension 1277 (61%) 335 (71%) 311 (56%) 631 (59%) <0.0001 159 (62%) 267 (59%) 851 (61%) 0.64 
Body mass index (kg/m^2) 28 (5.52) 29.4 (6.21) 27.7 (5.17) 27.5 (5.28) <0.0001 27.9 (5.64) 28.1 (5.51) 28 (5.5) 0.90 
Heart rate (beats/min) 80 (19) 80 (21) 80 (20) 80 (19) 0.88 86 (23) 78 (19) 79 (19) <0.0001 
Systolic blood pressure (mmHg) 124 (21) 133 (22) 121 (21) 122 (20) <0.0001 126 (20) 123 (20) 124 (22) 0.26 
Diastolic blood pressure (mmHg) 76 (13) 80 (14) 74 (13) 74 (12) <0.0001 78 (13) 74 (13) 76 (13) 0.003 
LVEF (%) 30 (25-35) 30 (25-35) 30 (24-35) 29 (25-35) 0.0004 30 (25-35) 30 (25-35) 30 (25-35) 0.11 
NT-proBNP (ng/L) 4138 (2249-8220) 3110 (1611-5796) 4500 (2495-8831) 3620 (2033-7506) <0.0001 3582 (2037-6754) 3968 (2364-7637) 3545 (2009-7384) 0.04 
eGFR (ml/min/1.73m^2) 66.7 (23.66) 70.9 (22.46) 64.2 (23.28) 66.1 (24.12) <0.0001 69.1 (25.28) 65.9 (22.67) 66.5 (23.64) 0.19 
% ACE target dose 50 (25-75) 100 25 (12.5-50) 25 (13-50) <0.0001 50 (25-100) 50 (16.7-62.5) 50 (25-62.5) <0.0001 
% BB target dose 25 (12.5-50) 50 (25-75) 25 (12.5-50) 25 (12.5-50) <0.0001 100 25 (12.5-50) 25 (12.5-50) <0.0001 
eGFR: estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction; NT-proBNP: N-terminal pro B-type natriuretic peptide 
    
 Figure S1: Flow-chart of the steps taken in model development phase and in the subsequent development of the Cox-models. 
 
  
 
  
Imputation
•We imputed the data 5 times 
usingmulti-chain Monte Carlo methods 
Gibbs sampling 
Bootstrap 
samples
•Using the 5 imputed datasets.
•We performed 1000 bootstrap samples in each imputed dataset
stepwise 
regression 
•Selected variables >40% of bootrap 
samples
Cox 
regression 
models
•Use selected variables from previous 
step and apply them in the four 
methods: propensity score 
matching, IPW, inverse probability 
weighting and multivariate model.
 Figure S2: Hazard ratio curve for achieved ACE-inhibitor/ARB and beta-blocker doses. These hazard curves are comparing achieved doses to 
achieving recommended doses using a pspline function. 
 
 
 
